MYRTO GİANNOPOULOU, KATERİNA TARASSİ, GLYKERİA TSOUKA, CHRİSTALLENİ CHRİSTODOULİDOU, IOANNİS STEFANİDİS, THEODOROS ELEFTHERİADİS
Experimental and Clinical Transplantation - 2022;20(7):695-697
Chronic active antibody-mediated rejection is the leading cause of kidney transplant failure. Although various immunosuppressive agents have been tested, rituximab included, presently there is no effective treatment. There are reports about the beneficial role of certain immunosuppressive protocols that include rituximab to reduce donor-specific antibodies, the cause of chronic active antibody-mediated rejection. If an immunosuppressive agent reduces donorspecific antibodies, its administration before the occurrence of chronic active antibody-mediated rejection may be beneficial. We describe a case of a renal transplant recipient with recurrent membranous nephropathy and recent development of donorspecific antibodies but without histological evidence of active antibody-mediated rejection. The patient received 3 weekly doses of rituximab for recurrent membranous nephropathy, and complete remission was achieved. One year after, he has preserved an excellent renal function without proteinuria. However, repeated measurements of donor-specific antibodies revealed that rituximab only modestly reduced donor-specific antibodies. Donor-specific antibody levels remained considerably higher than the laboratory reference value. Thus, rituximab alone may not have a role to prevent chronic active antibodymediated rejection in patients with donor-specific antibodies.
